
Source briefing
Seroprevalence of Influenza A(H5N1) Virus in Domestic Cats at Epicenter of Dairy Cattle Outbreaks, California, USA, 2024–2026
I. G. Bemis et al.
Read →
Source briefing
Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Status: Opinion
Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Status: Opinion
Read →
Source briefing
Human medicines European public assessment report (EPAR): Evlarco, obicetrapib,ezetimibe, Status: Opinion
Human medicines European public assessment report (EPAR): Evlarco, obicetrapib,ezetimibe, Status: Opinion
Read →
Source briefing
Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Itvisma, onasemnogene abeparvovec, Date of authorisation: 30/06/2026, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Date of authorisation: 26/07/2018, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Rxulti, brexpiprazole, Date of authorisation: 26/07/2018, Revision: 10, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 9, Status: Authorised
Human medicines European public assessment report (EPAR): Padcev, enfortumab vedotin, Date of authorisation: 13/04/2022, Revision: 9, Status: Authorised
Read →
Source briefing
EMA and EISMEA boost cooperation to accelerate health innovations
EMA and the European Innovation Council and SMEs Executive Agency (EISMEA) have strengthened their cooperation in support of health innovation in the European Union (EU). Today…, Enabling innovation is central to our public health mission to bring new…
Read →
Source briefing
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026
Twelve new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended twelve medicines for approval at its July 2026 meeting.The committee…, CHMP statistics Key figures from the July 2026 CHMP meeting are represented in the graphic below. © European Medicines…
Read →
Source briefing
World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach
While Europe has made steady progress in preventing hepatitis B and C the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat.
Read →
Source briefing
World Hepatitis Day 2026: Ensuring that life-saving interventions are accessible to everyone who needs them is a common challenge
World Hepatitis Day is an opportunity to raise awareness of the risk of contracting hepatitis and the health threats it can bring, while at the same time recognising the progress Europe has made to strengthen prevention.
Read →